Scholarlink

Background <p>Therapies with chimeric antigen receptor (CAR) T‑cells represent a&#xa0;new treatment option for patients with relapsed or refractory hematologic malignancies.</p> Objective <p>In which areas is the quality of life of patients receiving CAR T‑cell therapy impaired from the clinician’s perspective?</p> Methods <p>Mixed-methods study with questionnaires and interviews. Participants were presented with a&#xa0;list of quality of life domains that can be impaired after CAR-T&#xa0;cell therapy according to a&#xa0;systematic review. This list contained 94&#xa0;areas, some with subareas, so that a&#xa0;total of 112 different issues were included.</p> Results <p>Two hematologists and four nurses took part in the survey. Of the 112 issues surveyed, 27&#xa0;met the criteria for both relevance and priority. Of these 27&#xa0;issues, the following were rated as most relevant: lack of energy, distress, worry about disease recurrence and worsening health, fever or chills, hallucinations, confusion, and difficulty writing.</p> Conclusion <p>CAR-T&#xa0;cell therapies can specifically impair quality of life. These impairments are probably underreported in previous studies because specific questionnaires are still lacking. When informing patients about the possible consequences of CAR-T&#xa0;cell therapy, cognitive impairments (e.g., hallucinations, confusion) and impairments due to infections should be mentioned in addition to fatigue and distress. Psycho-oncologists should be familiar with the specific spectrum of side effects of CAR-T&#xa0;cell therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lebensqualität bei CAR-T-Zell-Therapie. Eine Mixed-methods-Studie

  • 期刊论文

  • 发表日期：

    2025年3月10日

查看全文
  • Susanne Singer,
  • Jonas Wißkirchen,
  • Nora Rogmann,
  • Manuela Krämer,
  • Daniel Wenzel,
  • Mara Schäfer,
  • Georg Heß,
  • Isabella Werry,
  • Oliver Bayer

摘要

Background

Therapies with chimeric antigen receptor (CAR) T‑cells represent a new treatment option for patients with relapsed or refractory hematologic malignancies.

Objective

In which areas is the quality of life of patients receiving CAR T‑cell therapy impaired from the clinician’s perspective?

Methods

Mixed-methods study with questionnaires and interviews. Participants were presented with a list of quality of life domains that can be impaired after CAR-T cell therapy according to a systematic review. This list contained 94 areas, some with subareas, so that a total of 112 different issues were included.

Results

Two hematologists and four nurses took part in the survey. Of the 112 issues surveyed, 27 met the criteria for both relevance and priority. Of these 27 issues, the following were rated as most relevant: lack of energy, distress, worry about disease recurrence and worsening health, fever or chills, hallucinations, confusion, and difficulty writing.

Conclusion

CAR-T cell therapies can specifically impair quality of life. These impairments are probably underreported in previous studies because specific questionnaires are still lacking. When informing patients about the possible consequences of CAR-T cell therapy, cognitive impairments (e.g., hallucinations, confusion) and impairments due to infections should be mentioned in addition to fatigue and distress. Psycho-oncologists should be familiar with the specific spectrum of side effects of CAR-T cell therapies.